Primary cytomegalovirus phosphoprotein 65-specific CD8 + T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients

Journal of Infectious Diseases

Volumn 204, Issue 11, 2011, Pages 1663-1671

  Pipeling, Matthew R ^a   John, Emily R ^a   Orens, Jonathan B ^a   Lechtzin, Noah ^a   McDyer, John F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD8 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS PHOSPHOPROTEIN; VIRUS PHOSPHOPROTEIN 65;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EFFECTOR CELL; FEMALE; GRAFT INFECTION; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN INDUCTION; RELAPSE;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERFERON-GAMMA; LUNG TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PHOSPHOPROTEINS; RECURRENCE; ROC CURVE; STATISTICS, NONPARAMETRIC; T-BOX DOMAIN PROTEINS; VIRAL MATRIX PROTEINS; VIREMIA; YOUNG ADULT;

EID: 80155198513     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir624     Document Type: Article

References (42)

1. Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186(suppl 1):S99-109.
2. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4:1219-6.
3. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-14.
4. Shah PD, McDyer JF. Viral infections in lung transplant recipients. Semin Respir Crit Care Med 2010; 31:243-54.
5. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46:840-6.
6. Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993; 67:5360-6.
7. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twentyseventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010; 29:1104-8.
8. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181:1391-6.
9. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297-310.
10. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003; 75:2064-8.
11. Kerschner H, Jaksch P, Karigl G, Popow-Kraupp T, Klepetko W, Puchhammer-Stockl E. Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival. Transplantation 2009; 87:1720-6.
12. Crough T, Khanna R. Immunobiology of human cytomegalovirus: From bench to bedside. Clin Microbiol Rev 2009; 22:76-98.
13. Scheinberg P, Melenhorst JJ, Brenchley JM, et al. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood 2009; 114:5071-80.
14. Glimcher LH, Townsend MJ, Sullivan BM, Lord GM. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol 2004; 4:900-11.
15. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655-69.
16. Sullivan BM, Juedes A, Szabo SJ, von HerrathM, Glimcher LH. Antigendriven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A 2003; 100:15818-23.
17. Intlekofer AM, Takemoto N, Kao C, et al. Requirement for T-bet in the aberrant differentiation of unhelped memory CD81 T cells. J Exp Med 2007; 204:2015-21.
18. Mayer KD, Mohrs K, Reiley W, et al. Cutting edge: T-bet and IL-27R are critical for in vivo IFN-gamma production by CD8 T cells during infection. J Immunol 2008; 180:693-7.
19. Pipeling MR, West EE, Osborne CM, et al. Differential CMV-specific CD81 effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol 2008; 181:546-56.
20. Oxenius A, Gunthard HF, Hirschel B, et al. Direct ex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD81 T lymphocyte activation in response to therapeutic manipulation of virus load. Eur J Immunol 2001; 31:1115-21.
21. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9:1214-22.
22. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-44.
23. Polic B, Hengel H, Krmpotic A, et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 1998; 188:1047-54.
24. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195:633-44.
25. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD81 T-cell immunity. Am J Transplant 2008; 8:1749-54.
26. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201:1031-6.
27. Gibson L, Piccinini G, Lilleri D, et al. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD81T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 2004; 172:2256-64.
28. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol 2006; 177:450-8.
29. SnyderCM, ChoKS, Bonnett EL, vanDommelen S, ShellamGR,HillAB. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 2008; 29: 650-9.
30. Karrer U, Sierro S, Wagner M, et al. Memory inflation: continuous accumulation of antiviral CD81 T cells over time. J Immunol 2003; 170:2022-9.
31. Hou S, Hyland L, Ryan KW, Portner A, Doherty PC. Virus-specific CD81 T-cell memory determined by clonal burst size. Nature 1994; 369:652-4.
32. Seder RA, Ahmed R. Similarities and differences in CD41 and CD81 effector and memory T cell generation. Nat Immunol 2003; 4: 835-42.
33. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4:225-34.
34. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: A critical role for IFN-gamma-producing CD41 T cells in protection against CMV disease. Blood 2003; 101:2686-92.
35. Sester U, Gartner BC, Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5: 1483-9.
36. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD81 T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009-21.
37. Joshi NS, Cui W, Chandele A, et al. Inflammation directs memory precursor and short-lived effector CD81 T cell fates via the graded expression of T-bet transcription factor. Immunity 2007; 27:281-95.
38. Hertoghs KM, Moerland PD, van Stijn A, et al. Molecular profiling of cytomegalovirus-induced human CD81 T cell differentiation. J Clin Invest 2010; 120:4077-90.
39. Kern F, Faulhaber N, Frommel C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30:1676-82.
40. Gyulai Z, Endresz V, Burian K, et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: Reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000; 181:1537-46.
41. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD41 and CD81 T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673-85.
42. Elkington R,Walker S, Crough T, et al. Ex vivo profiling of CD81-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77:5226-40.